View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Dirk Verbiesen ... (+2)
  • Dirk Verbiesen
  • Quirijn Mulder

Vopak/Preparing for take-off/BUY

With Vopak initiating some large new investments in recent years, investors should prepare for an acceleration in EBITDA growth, which together with improved financial KPIs should act as drivers for a re-rating of the shares in the coming 6-12 months, we believe. First, following a period of strategic divestments, Vopak is now well equipped for the years to come with a stronger return profile of its portfolio. Second, cash conversion has improved and should continue to be strong with promising p...

Kristof Samoy
  • Kristof Samoy

Vopak First Reaction - Withdrawal of support by First Nation for REEF ...

Yesterday, Energynow.ca published an article on the withdrawal of support by the Metlakatla First Nation citizens of Canada. Supposedly the Metlakatla First Nation's decision to retract its backing for the nearly completed REEF export project is rooted in concerns that it was not informed of an exclusivity agreement granting REEF an export monopoly, which could harm its economic interests in the rival Trigon terminal where it holds a 10% stake. A recent BC Supreme Court ruling allowing Metlakatl...

Hilde Van Boxstael ... (+5)
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Kristof Samoy
  • Mathijs Geerts Danau
  • Wim Lewi
Jacob Mekhael
  • Jacob Mekhael

Zealand Pharma Model update, multiple important catalysts ahead

We update our Zealand model following the company's recent CMD held in December 2025. Zealand outlined its plans to become a generational metabolic health company, as well as sharing clear targets with 5 product launches in the next 5 years, and to have 10+ clinical programs by 2030. Our model update incorporates adjusted milestone timing from Roche, removes dapiglutide, as well as a few small tweaks on the rare disease pipeline. All in all, this brings us to a new TP of DKK 960 (from DKK 1,120)...

Guy Sips ... (+10)
  • Guy Sips
  • Jacob Mekhael
  • Kristof Samoy
  • Livio Luyten
  • Lynn Hautekeete
  • Michiel Declercq
  • Thibault Leneeuw
  • Thomas Couvreur
  • Wim Hoste
  • Wim Lewi

Dynamic Top Pick List Update February 2026: Removing ASMi; Adding UCB

After today's changes (ASMi out, UCB in), we maintain a balanced approach in our Dynamic Top Pick List, with a particular emphasis on value stocks that have been overlooked. Our defensive holdings are overweight, including real estate, which stands to benefit from lower interest rates. We remove ASMi from our Dynamic Top Pick List as the recent share price performance has driven the valuation meaningfully ahead of fundamentals. Since early December, FY27 diluted EPS expectations have risen by a...

Baptiste Lebacq ... (+2)
  • Baptiste Lebacq
  • Jean-François Granjon

ODDO : 10 graphiques d’analyse : un pipeline de projets toujours solid...

Nous avons sélectionné 10 graphiques afin d’identifier les principaux drivers du secteur. Les Capex sont attendus en repli de 1.5% en 2026 après un rebond de 70% depuis le point bas de 2020. Cette baisse proviendra essentiellement du marché US (plus forte discipline compte tenu de points morts plus élevés). Nous privilégions SBM Offshore (Surperformance, OC 45 €), Vallourec (Surperformance, OC 22 € vs 20.8 €) et Technip Energies (Surperformance, OC 49 €) et adoptons une opinion plus prudente sur...

Baptiste Lebacq ... (+2)
  • Baptiste Lebacq
  • Jean-François Granjon

ODDO : 10 analysis charts: a pipeline of projects that remains solid

For the start of 2026, we have selected ten charts to identify the sector's main drivers. Capex is expected to fall by 1.5% in 2026 after a 70% rebound from the low point of 2020. This reduction will mainly come from the US market (greater discipline due to higher breakeven points). At this point in the year, we prefer SBM Offshore (Outperform, target price € 45), Vallourec (Outperform, target price € 22 vs € 20.8) and Technip Energies (Outperform, target price € 49) and have adopted a more caut...

David Vagman ... (+16)
  • David Vagman
  • CFA
  • Dirk Verbiesen
  • Francesca Ferragina
  • Jason Kalamboussis
  • Marc Hesselink
  • CFA
  • Marc Zwartsenburg
  • CEFA
  • Maxime Stranart
  • Michiel Vereycken
  • Quirijn Mulder
  • Reg Watson
  • CFA
  • Thymen Rundberg
  • Tijs Hollestelle

ING Benelux Favourites/Aedifica, Ageas, ASM International, Basic-Fit, ...

We refresh our ING Benelux Favourites list. We apply a fundamental bottom up approach in which we select stocks which provide the best upside within our Benelux coverage universe and these stocks need clear catalysts. Additions/deletions: We add the following names to the ING Benelux Favourites list: Ageas: Ageas has done multiple deals; its most recent purchase of the 25% stake BNP Paribas had in its Belgian ops, is an accretive deal and we believe makes the Belgian operations ready for a pot...

Kristof Samoy
  • Kristof Samoy

Vopak Maersk not to invest in Vopak's brownfield in the port of Antwer...

Last Friday evening, Belgian newspaper De Tijd reported that Vioneo has halted plans for a €1.5bn green plastics plant in the Port of Antwerp. The project will instead be developed in China. Vioneo focuses on new technology to produce plastics without fossil feedstocks. The Maersk subsidiary had selected Antwerp in 2024 for its first large scale facility, designed to produce 300,000 tonnes of “green plastic” annually. The Vioneo plant was planned for the former Gunvor refinery site, a brownfield...

Hilde Van Boxstael ... (+3)
  • Hilde Van Boxstael
  • Mathijs Geerts Danau
  • Wim Lewi
Jacob Mekhael
  • Jacob Mekhael

Zealand Pharma Enters agreement with DCAI to use AI supercomputer for ...

Zealand announced that it entered into an agreement with DCAI to use Gefion AI supercomputer to accelerate drug discovery and support its Metabolic Frontier 2030 strategy, to deliver five launches, +10 clinical pipeline programs, and industry-leading cycle times from idea to clinic by 2030.The platform supports advanced characterization, simulation, and generative AI modelling for drug discovery and design. Financial terms were not disclosed. DKK 1,120 TP and BUY maintained.

 PRESS RELEASE

Zealand Pharma enters agreement with DCAI to use Gefion AI supercomput...

Zealand Pharma enters agreement with DCAI to use Gefion AI supercomputer to accelerate drug discovery and support Metabolic Frontier 2030 strategy Press release – No. 2 / 2026 Zealand Pharma enters agreement with DCAI to use Gefion AI supercomputer to accelerate drug discovery and support Metabolic Frontier 2030 strategy Access to Gefion, Denmark’s flagship AI supercomputer, gives Zealand Pharma access to unprecedented computational power, enabling large-scale modeling, prediction, and optimization of drug candidatesAgreement will support Zealand Pharma’s Metabolic Frontier 2030 strategy ...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch